Rani Therapeutics Approves Key Proposals at Annual Meeting

Rani Therapeutics Holdings ( (RANI) ) has issued an announcement.

On May 28, 2025, Rani Therapeutics Holdings held its annual meeting of stockholders where key proposals were approved. The stockholders elected directors to serve until the 2026 annual meeting and ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (RANI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Rani Therapeutics Holdings stock, see the RANI Stock Forecast page.

Spark’s Take on RANI Stock

According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.

Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.

To see Spark’s full report on RANI stock, click here.

More about Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative oral biologics. The company is known for its proprietary technology aimed at transforming injectable biologics into oral pills, targeting a significant market opportunity in improving patient compliance and expanding treatment options.

Average Trading Volume: 400,758

Technical Sentiment Signal: Sell

Current Market Cap: $35.72M

For detailed information about RANI stock, go to TipRanks’ Stock Analysis page.